Gryphus Announces Issuance of U.S. Patent on Sialidase Technology Platform; Applications in Diagnosis and Prognosis of Infectious Disease
BIRMINGHAM, Ala. -- Gryphus Diagnostics, LLC, a leading developer of technologies and products for the diagnosis of infectious disease, today announced the recent issuance of a U.S. patent covering its sialidase technology platform. Patent No. 6,512,100 covers a series of chromogenic substrate compounds for sialidases of bacterial, viral, protozoa, and vertebrate (including human) origin and methods of diagnosis and prognosis of sialidase-related diseases using these substrate compounds.
Patent No. 6,512,100 is currently employed in Gryphus' BVBLUE product, the company's FDA released and internationally distributed product used to detect vaginal fluid sialidase associated with Bacterial Vaginosis (BV).
BV, the most common form of infectious vaginitis, accounts for approximately 50 million annual patient visits worldwide and has been strongly associated with pre-term birth, delivery of a low-birth-weight infant, post-surgical infections, as well as an increased risk of HIV and other sexually transmitted diseases (STDs). Women with BV typically exhibit 100- to 1,000-fold increased levels of pathogenic bacteria, including those that secrete sialidase, in their vaginal fluid compared with healthy controls.
"The issuance of this patent significantly expands Gryphus' intellectual property position and further strengthens our market strategy of providing innovative technologies and products for the reliable, cost-effective, and rapid diagnosis and management of infectious disease," says Stephen C. Johnson, PhD, co-founder and president of Gryphus Diagnostics. "We have an extensive product pipeline under development utilizing this patented technology platform in diagnostic products for infectious disease including products for periodontal disease, influenza virus and T. cruzi infection."
Gryphus Diagnostics, LLC, is an emerging biotechnology company specializing in the discovery, development, manufacture and marketing of rapid, point-of-care (POC) diagnostic tests for infectious disease, especially those related to women's health. Gryphus' products are available worldwide for use in physician's offices, hospitals, and clinical laboratories through a network of established distributors and licensees.
Source: Gryphus Diagnostics, LLC
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
